The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...

InMed Pharmaceuticals Inc., a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug ...

Aclaris Therapeutics (ACRS) announced the availability of a new publication describing properties of Aclaris Therapeutics’ ATI-2138, a novel ...

Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...

Diabetes, as defined by the World Health Organization, represents a collection of metabolic diseases characterized primarily by hyperglycemia, which can ...

A new slew of beauty products are focused on strengthening the skin barrier to mitigate other issues. Here, experts explain ...

More information about the 2025 AAAAI / WAO Joint Congress can be accessed here.

Preclinical studies have shown their potential to reduce inflammation and modulate immune responses in diseases like rheumatoid arthritis and lupus.

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...